SCHEMBL7218428

SCHEMBL7218428

COc1ccc(CN(C)C2CCOCC2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 2/20 0.51
HRH4 Q9H3N8 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CYP2D6 P10635 2/20 0.44
HRH1 P35367 1/20 0.44
KCNH2 Q12809 1/20 0.44
GAA P10253 2/20 0.43
PYCR1 P32322 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CYP2C19 P33261 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
APLNR P35414 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
CHEK1 O14757 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12909329 0.87 HRH3 (0.64) PDE1BHRH4HRH3ALDH1A1SMN1; SMN2
SCHEMBL29336473 0.85 HRH3 (0.67) PDE1BHRH4HRH3ALDH1A1KDM4E
SCHEMBL19390961 0.84 HRH3 (0.70) PDE1BHRH4HRH3ALDH1A1CYP2D6
SCHEMBL17297950 0.83 HRH3 (0.50) PDE1BHRH4HRH3ALDH1A1SMN1; SMN2
SCHEMBL16193406 0.82 HRH3 (0.53) PDE1BHRH4HRH3ALDH1A1NPC1
SCHEMBL28515493 0.82 SMN1; SMN2 (0.44) PDE1BALDH1A1SMN1; SMN2GAAL3MBTL1
SCHEMBL19477795 0.81 HRH3 (0.49) PDE1BHRH4HRH3ALDH1A1SMN1; SMN2
SCHEMBL7216670 0.81 HRH3 (0.51) PDE1BHRH4HRH3ALDH1A1NPC1
SCHEMBL5179064 0.81 HRH3 (0.51) PDE1BHRH4HRH3ALDH1A1NPC1
SCHEMBL7222245 0.81 HRH3 (0.51) HRH4HRH3ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed